Clover Biopharmaceuticals, Ltd. provided updates on business and R&D pipeline development. Moreover, demand in China continues to shift from trivalent to seasonal quadrivalent influenza vaccine options, which accounted for a majority of doses (70%)4 in 2022. Commercialization Plans: Commercial launch in mainland China is on track to occur in H2-2023.

Adimmune commenced production of AdimFlu-S (QIS) in Q1-2023, and importation into mainland China and subsequent batch release testing are expected to occur in third quarter-2023. Sales are expected to be accretive to Clover's earnings starting in 2023 and contribute meaningful growth in 2024 and beyond. Commercial Capabilities: Clover has now completed buildup of its initial commercial team in China to support commercialization of AdimFlu- S (QIS) in 2023 as planned, and it announced in May 2023 a collaboration to leverage Kyuan Trade's extensive sales and distribution network to complement in-house capabilities and maximize access to AdimFlu-S.RSV Vaccine Candidate (SCB-1019): SCB-1019 is Clover's RSV vaccine candidate based on prefusion-stabilized F (PreF) protein leveraging the validated Trimer-Tag platform.

Clover expects to be among the first Chinese RSV PreF vaccine companies to enter human clinical trials and plans to disclose additional preclinical data and development plans in H2-2023; Market Opportunity: With RSV being a leading cause of acute respiratory infection, disease and death in the elderly and infants, the market for RSV vaccines is expected to potentially reach over USD 10 billion in peak annual sales globally, which would make it comparable to the market size for pneumococcal vaccines. Compared to native TPO-based therapy which is commercially available in China, SCB-219M could potentially overcome reduced efficacy due to anti-drug antibodies (ADA) and achieve a more convenient dosing regimen attributed to its longer half-life. Interim Phase 1 clinical trial data is anticipated in fourth quarter-2023.